

Tablica 10. Prvih 30 lijekova prema financijskoj potrošnji izraženo u kunama u 2021. godini, bolnička potrošnja

RBR	ATK	INN	UKUPNI IZNOS
1	L01XC18	pembrolizumab	318.517.414
2	L01EL01	ibrutinib	145.876.430
3	L01XC03	trastuzumab	137.571.323
4	L01XC07	bevacizumab	127.186.874
5	L01XC13	pertuzumab	119.531.948
6	L01XC32	atezolizumab	102.367.095
7	L02BB04	enzalutamid	91.518.997
8	L01XC17	nivolumab	88.339.059
9	J06BA02	imunoglobulini, humani, za i.v. primjenu	87.222.358
10	L01XC24	daratumumab	83.016.092
11	L04AX04	lenalidomid	76.663.762
12	L01EF01	palbociklib	76.318.852
13	L04AA36	okrelizumab	75.248.157
14	L02BX03	abirateron	74.143.694
15	L01EF02	ribociklib	58.760.718
16	M09AX07	nusinersen	57.856.508
17	S01XA27	voretigen neparvovek	56.237.430
18	L04AB02	infliksimab	56.194.701
19	L01XC02	rituksimab	53.308.489
20	L01XC14	trastuzumab emtanzin	51.866.004
21	B05AA01	albumin, ljudski	49.719.898
22	B05BB01	elektroliti	49.077.275
23	L01CD01	paklitaksel	43.484.607
24	J01DH02	meropenem	41.037.020
25	L01EE01	trametinib	36.173.708
26	L01EX01	sunitinib	35.992.303
27	B01AB05	enoksaparin	35.161.091
28	L01EA03	nilotinib	34.747.987
29	L01EC02	dabrafenib	33.058.815
30	L01XC06	cetuksimab	32.511.571